Disease Modifying Trials

The shifting landscape of clinical trials over the past few years has been highly significant. Whilst there are still many studies looking to improve symptoms, we are now seeing a growing momentum in trials that are aiming to slow disease progression.

Simon JG Lewis is Professor of Cognitive Neuroscience at University of Sydney. He is on the Program Committee for the 5th World Parkinson Congress and spoke at the 4th World Parkinson Congress. 

Ideas and opinions expressed in this post reflect that of the author(s) solely. They do not reflect the opinions or positions of the World Parkinson Coalition®